Real-world blood drug concentration analysis of zanubrutinib in the treatment of malignant lymphoma: A single-center observational study on the relationship between exposure and efficacy/safety

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600125549

Enrollment

Unknown

Registered

2026-05-28

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent/refractory (R/R) and first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL)

Interventions

Zanubrutinib treatment group:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Chinese patients aged 18 years or above; 2. Pathologically confirmed CLL/SLL, MCL or WM; 3. ECOG score <= 2; 4. Treated with Zanubrutinib (160 mg twice daily).

Exclusion criteria

Exclusion criteria: 1. Severe liver damage (Child-Pugh C grade); 2. Active bleeding; 3. Concurrent use of potent CYP3A4 inhibitors/inducers; 4. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
progression free survival;objective remission rate;	—

Secondary

Measure	Time frame
The incidence rate of adverse events of grade 3 or above;Blood drug concentration compliance rate (Ctrough 20-50 ng/mL);	—

Countries

China

Contacts

Public ContactFeng Tingting

Shanghai General Hospital

ycttfeng@163.com+86 21 63240090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026